Nirogacestat is approved by the USFDA for desmoid tumors

Nirogacestat is approved by the USFDA for desmoid tumors

Share This Post

The Food and Drug Administration authorized nirogacestat (OGSIVEO, SpringWorks Therapeutics, Inc.) on November 27, 2023, for adult patients with advancing desmoid tumors needing systemic treatment. This is the initial authorized therapy for desmoid tumors.

A study called DeFi (NCT03785964) looked at how well it worked. It was an international, multicenter, randomized (1:1), double-blind, placebo-controlled experiment with 142 patients who had desmoid tumors that were getting worse and could not be treated with surgery. Patients were qualified if the desmoid tumor had advanced within 12 months after screening. Participants were randomly assigned to take 150 mg of nirogacestat or a placebo orally twice a day until illness progression or intolerable toxicity.

Progression-free survival (PFS) calculated by RECIST v1.1 by a blinded independent central review or clinical progression assessed by the investigator and reviewed independently was the main way to measure how well the treatment worked. The median progression-free survival (PFS) was not determined in the nirogacestat group (95% CI: not determined) and was 15.1 months (95% CI: 8.4, not determined) in the placebo group. The hazard ratio (HR) was 0.29 (95% CI: 0.15, 0.55) with a p-value of less than 0.001. An initial investigation of progression-free survival (PFS) using solely radiographic progression revealed a hazard ratio of 0.31 (95% CI: 0.16, 0.62).

The objective reaction rate (ORR) was an extra measure of effectiveness. The Objective Response Rate (ORR) was 41% (95% CI: 29.8, 53.8) for participants in the nirogacestat group and 8% (95% CI: 3.1, 17.3) for those in the placebo group (p-value=<0.001). The improvement in patient-reported worst pain from the beginning of the study, which favored the nirogacestat group, further confirmed the efficacy results.

The prevalent adverse effects included diarrhea, ovarian toxicity, rash, nausea, exhaustion, stomatitis, headache, stomach discomfort, cough, alopecia, upper respiratory tract infection, and dyspnea.

The suggested nirogacestat dosage is 150 mg taken orally twice a day, with or without food, until illness progresses or there is unacceptable toxicity. Each dose of 150 mg is comprised of three 50 mg pills.

View full prescribing information for OGSIVEO.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy